TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05344443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo that looks and tastes like Lemborexant tablets
Study: NCT04771572
Drug: LP-118
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
Study: NCT06576180
Drug: Anti-PD-1 Drugs
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT05532111
Drug: Glucocorticoid combined with cyclophosphamide induction + maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
Study: NCT05348772
Drug: AmnioPul-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem / stromal cells, MSC
Study: NCT06423898
Drug: Experimental regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis
Study: NCT06423898
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous antibiotic infusion during 42 days for Infective Endocarditis
Study: NCT00261586
Drug: aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04730596
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline in a labeled syringe
Study: NCT05644054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
Study: NCT04911777
Drug: Pentarlandir™ UPPTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
Study: NCT04911777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Study: NCT05153070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
Study: NCT06209580
Drug: AMT-253 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06201923
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00046137
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00239265
Drug: Tamuslosin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05024188
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
Study: NCT04687969
Drug: [18F]DCFPyL
Approvals — FDA: no, EMA: no, PMDA: no
Description: will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
Study: NCT05006287
Drug: Non-vitamin K oral anticoagulants (NOACs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated.
Study: NCT06699420
Drug: Qishenyiqi dripping pills 1 bag, three times a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Study: NCT06699420
Drug: Placebo 1 bag, three times a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 bag once, three times a day, 12 months
Study: NCT04610801
Drug: Nasal Spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to placebo and Xlear
Study: NCT00133419
Drug: Vitamin + Zinc + micronutrient mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133419
Drug: Vitamin A + Zinc
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06575478
Drug: Dihuang Baoyuan Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihuang Baoyuan Granules
Study: NCT05584956
Drug: L_carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[
Study: NCT05808374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05533593
Drug: Aminoglycoside
Normalized name: Aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatients using aminoglycoside
Study: NCT05936060
Drug: PLACEBO COMPARATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of plasmalyte as a vehicle for MSC
Study: NCT06541457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 subjects for placebo
Study: NCT04582539
Drug: INCB000928
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB000928 will be administered once daily.
Study: NCT05188261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
Study: NCT05653479
Drug: UPB-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPB-101 Subcutaneous injection
Study: NCT00357981
Drug: ORTHO EVRA, the contraceptive patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05018182
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
Study: NCT05018182
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
Study: NCT03051451
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
Study: NCT06431932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a corresponding number of placebo capsules for two consecutive days.
Study: NCT05051189
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
Study: NCT05440045
Drug: 6MW3211
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MW3211 injection, 30mg/kg, Q2W
Study: NCT05598424
Drug: Oral Glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
Study: NCT06344195
Drug: Naproxen Sodium 550mg
Normalized name: Naproxen Sodium 550mg Oral tablet
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550mg (as needed, SOS) for 6 days
Study: NCT05382819
Drug: FRTX-02 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DYRK-1A Inhibitor
Study: NCT05382819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT06378593
Drug: 3HP-2827
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.
Study: NCT06535334
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
Study: NCT05408208
Drug: Intralesional Injection of Methotrexate
Normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
Study: NCT04267809
Drug: Calcium and Vitamin D
Normalized name: Wellesse Calcium and Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
Study: NCT05179889
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks~mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week
Study: NCT05179889
Drug: mFOLFOX 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
Study: NCT05632861
Drug: HuHuangLianzonggan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
Study: NCT06030297
Drug: ZTlido 1.8 % Topical System
Normalized name: ZTlido 1.8 % Topical System
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZTLI(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4. Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base and also contains the following inactive ingredients: butylated hydroxytoluene, dipropylene glycol, isostearic acid, mineral oil, polyisobutylene, silicone dioxide, styrene/isoprene/styrene block copolymer, and terpene resin. DO (lidocaine topical system) 1.8% is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of ZTLIDO is 10 cm × 14 cm × 0.08 cm. Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-
Study: NCT04772781
Drug: S (+) - Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S (+) - Ibuprofen + placebo of Ibuflex®
Study: NCT04772781
Drug: Ibuflex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuflex® + placebo of S (+) - Ibuprofen
Study: NCT04760431
Drug: Taxanes
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel: 75 mg/m2, administered by IV infusion every 3 weeks Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks
Study: NCT04760431
Drug: Tyrosine kinase inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib: 400mg po within 30 minutes after a meal, QD, every 3 weeks Neratinib: 240mg po QD, every 3 weeks Tucatinib: 300mg po Q12H
Study: NCT05652907
Drug: FSD201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT05652907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matched to FSD201 for oral administration.
Study: NCT05308953
Drug: NVG-291
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVG-291 is a drug injected under the skin (subcutaneous).
Study: NCT05122182
Drug: Repagermanium Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-C chemokine receptor type 2 (CCR2) antagonist placebo
Study: NCT05925647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9% infusion
Study: NCT05057130
Drug: Doxorubicin, Cisplatin, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT05057130
Drug: Doxorubicin, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT06310733
Drug: LGG
Normalized name: LGG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.
Study: NCT06310733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
Study: NCT04903158
Drug: test SHR3680 tablets
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)
Study: NCT04903158
Drug: reference SHR3680 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).
Study: NCT05244070
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04767841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus celecoxib 200 mg capsule
Study: NCT05360147
Drug: Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
Study: NCT06171087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT05040425
Drug: Zi-Yin-Liang-Ge-San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
Study: NCT04634344
Drug: DZD2269
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
Study: NCT04863001
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
Study: NCT05501821
Drug: KBA1412
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A, B, C
Study: NCT04900428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT05453227
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
Study: NCT05251337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
Study: NCT04940273
Drug: Remifentanil Injection [Ultiva]
Normalized name: remifentanil Injection [Ultiva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
Study: NCT04219540
Drug: XR-NTX
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
Study: NCT05388279
Drug: JS012
Normalized name: Janus Kinase Inhibitor JS012
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS012, i.v., q3w
Study: NCT05541003
Drug: NBT-NM108
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will consume NBT-NM108 in the form of 2 muffins daily.
Study: NCT05780125
Drug: FibCLOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration
Study: NCT06369363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be assigned to 1 week of transdermal placebo patch.
Study: NCT06369363
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
Study: NCT04939987
Drug: Oxycodone-Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Control Cohort (One treatment selected)
Study: NCT04939987
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental Cohort (Multimodal Approach)
Study: NCT04939987
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Cohort (Multimodal Approach)
Study: NCT00001030
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06092788
Drug: NTP42:KVA4 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule
Study: NCT06092788
Drug: NTP42:KVA4 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid
Study: NCT06564298
Drug: SOX/XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
Study: NCT05258266
Drug: ZX-101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q.D., oral dosing
Study: NCT06577077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 01 tablet in the morning and 01 tablet in the evening for 14 days
Study: NCT06379997
Drug: Intra-articular infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Study: NCT05915247
Drug: HER-096
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single dose via s.c. injection
Study: NCT05915247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single dose via s.c. injection
Study: NCT04977427
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
Study: NCT04977427
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
Study: NCT05602649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally ingested
Study: NCT05435729
Drug: DSP-9632P 27.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of DSP-9632P 27.5 mg
Study: NCT05435729
Drug: DSP-9632P 82.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of DSP-9632P 82.5 mg
Study: NCT05435729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for DSP-9632P
Study: NCT05435729
Drug: DSP-9632P 55.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of DSP-9632P 55.0 mg
Study: NCT05435729
Drug: Levodopa formulation
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of Levodopa formulation
Study: NCT05858788
Drug: SAR441566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06129604
Drug: TPST-1495
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
Study: NCT04594772
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).